Makers of generic and brand-name drugs say that agreements to keep generic drugs off the market for a certain period do not cost consumers more, but in fact save money by avoiding expensive patent litigation. The Federal Trade Commission is suing to have the patent settlements ruled anti-competitive.

Full Story:

Related Summaries